Sera Prognostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 09, 2023 at 04:13 pm EDT
Share
Sera Prognostics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 0.123 million compared to USD 0.078 million a year ago. Net loss was USD 10.54 million compared to USD 11.52 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.37 a year ago.
For the six months, sales was USD 0.223 million compared to USD 0.116 million a year ago. Net loss was USD 21.11 million compared to USD 23.73 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.77 a year ago.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
SERA PROGNOSTICS, INC. 
